Form 4: Madrigal CEO's Equity Grant and Tax Sale

Madrigal Pharmaceuticals CEO William John Sibold received new equity grants and sold shares to cover tax obligations.

Summary

• President and CEO William John Sibold of Madrigal Pharmaceuticals, Inc. received a grant of 14,995 restricted stock units (RSUs) on March 4, 2026.
• These RSUs are scheduled to vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030, contingent on continued service.
• Sibold also received a grant of 18,743 stock options on March 4, 2026, with an exercise price of $434.80 per share.
• The stock options vest 25% on March 4, 2027, and then 6.25% on the last day of each successive three-month period thereafter, contingent on continued service, with an expiration date of March 4, 2036.
• On March 6, 2026, 1,663 shares of common stock were sold at a price of $431.94 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, William John Sibold beneficially owns 161,829 shares of common stock and 18,743 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive commitment through long-term equity incentives, despite a minor tax-related share sale which is a routine event.

Positives

• Grant of 14,995 restricted stock units (RSUs) to President and CEO William John Sibold, aligning his interests with long-term shareholder value.
• Grant of 18,743 stock options to President and CEO William John Sibold, providing further incentive for company performance and growth.

Negatives

• Sale of 1,663 shares of common stock by the CEO to cover tax withholding obligations, resulting in a reduction of direct beneficial ownership.

Risks

• Vesting of restricted stock units and stock options is contingent upon the Reporting Person's continued service with the Issuer on each specified vesting date.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend through March 2030 and March 2036, respectively, indicating a long-term incentive structure for the CEO that aligns his future compensation with the company's performance over an extended period.

Management Comments

• The sale of shares to cover tax withholding obligations was automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that executive equity grants and subsequent tax-related sales are standard practices in the biotechnology and pharmaceutical industries for executive compensation and retention, aligning management incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• NA (Form 4 filings primarily report individual insider transactions and do not typically provide data for direct comparison to industry-wide compensation benchmarks or specific company projects.)

Stakeholder Impact

• Shareholders: The equity grants align the CEO's interests with long-term shareholder value, potentially fostering sustained performance and strategic decision-making.
• Employees: The compensation structure for the CEO may set a precedent or reflect the company's overall approach to executive incentives and retention.

Next Steps

• Continued vesting of 25% of restricted stock units annually on March 4, 2027, 2028, 2029, and 2030, contingent on the CEO's continued service.
• Continued vesting of stock options, with 25% on March 4, 2027, and 6.25% quarterly thereafter, contingent on the CEO's continued service, until their expiration on March 4, 2036.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants and a tax-related share sale, which are standard events and do not provide new fundamental information to warrant a change in investment recommendation. The grants align the CEO's interests with long-term performance, which is generally positive, but not a catalyst for a 'buy' or 'sell' decision based solely on this filing.

Keywords

MDGL, Madrigal Pharmaceuticals, Form 4, insider transaction, stock grant, RSU, stock option, CEO, executive compensation, equity award